Comparing two timed drug schedules for thin, fragile bones after menopause
Compares two drug schedules in people with postmenopausal osteoporosis aged 50 to 90.
Plain-language title generated from the registry record
Registry title: Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients
Key facts
- Where
- Taipei, TaiwanSee the site
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT06938152, who can take part
Where in Taiwan
- National Taiwan University HospitalTaipei, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- National Taiwan University Hospital
- Trial code
- NCT06938152
- Record updated
- 23 June 2026
- Original description
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.Read full original descriptionShow less
Effects of Cycle Therapy With Romosozumab and Denosumab 2 Years vs 1 Year Romosozumab Followed by 1 Year Denosumab in Postmenopausal Osteoporosis Patients-A Randomized Control Trial
This study is a prospective, randomized, controlled clinical trial comparing the efficacy of a 24-month cyclic therapy regimen (6 months of Romosozumab followed by 6 months of Denosumab, repeated for two years) versus a traditional sequential treatment regimen (12 months of Romosozumab followed by 12 months of Denosumab). The goal is to determine which approach yields better therapeutic outcomes and to optimize drug strategies for osteoporosis patients.
Inclusion: 1. Postmenopausal women aged 50-90 years; 2. BMD T-score ≤ -3.0 at any lumbar vertebra; 3. Physically and mentally capable of understanding and complying with the study protocol and follow-up; 4. Signed informed consent.
Exclusion: 1. Previous osteoporosis treatment within the past two years, including Romosozumab, Teriparatide, Denosumab, Alendronate, Ibandronate, Zoledronic Acid, Risedronate, Raloxifene, or Bazedoxifene; 10. Planned dental procedures (e.g., extractions, implants) within the next year; 2. Allergy to Romosozumab or Denosumab; 4. Autoimmune disease; 5. Chronic steroid use (e.g., Chronic Obstruction Pulmonary Disease patients); 7. Metabolic bone diseases; 9. Cancer patients (except for in situ carcinoma and non-melanoma skin cancer, unless fully treated and in remission for five years); 11. History of stent placement, myocardial infarction, stroke, or coronary artery disease; 12. Renal disease (Creatinine > 1.5 mg/dL) or dialysis patients; 3. Secondary osteoporosis; 6. Hypercalcemia or hypocalcemia; 8. Primary or metastatic bone tumors; 13. Smoking more than one pack per day (except for those who have quit for over ten years).